Germline cells in ovarian surface epithelium of mammalians: a promising notion.

Reprod Biol Endocrinol

Department of Obstetrics and Gynecology, Inonu University, Medical Faculty, Malatya, Turkey.

Published: December 2012

It is a long held doctrine in reproductive biology that women are born with a finite number of oocytes and there is no oogenesis during the postnatal period. However, recent evidence challenges this by showing the presence of germ line stem cells in the human ovarian surface epithelium (OSE), which can serve as a source of germ cells, and differentiate into oocyte like structures. Postnatal renewal of oocytes may have enormous therapeutic potential especially in women facing the risk of premature ovarian failure idiopathically or iatrogenically after exposure to gonadotoxic chemotherapy and radiation for cancer therapy.This article reviews current knowledge on germ line stem cells in human OSE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566967PMC
http://dx.doi.org/10.1186/1477-7827-10-112DOI Listing

Publication Analysis

Top Keywords

ovarian surface
8
surface epithelium
8
germ stem
8
stem cells
8
cells human
8
germline cells
4
cells ovarian
4
epithelium mammalians
4
mammalians promising
4
promising notion
4

Similar Publications

Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography.

Eur J Nucl Med Mol Imaging

January 2025

Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.

Objectives: Mesothelin (MSLN) is an antigen that is overexpressed in various cancers, and its interaction with tumor-associated cancer antigen 125 plays a multifaceted role in tumor metastasis. The serum MSLN expression level can be detected using enzyme-linked immunosorbent assay; however, non-invasive visualization of its expression at the tumor site is currently lacking. Therefore, the aim of this study was to develop a molecular probe for imaging MSLN expression through positron emission tomography (PET).

View Article and Find Full Text PDF

Calreticulin (CRT) is a 46 kDa highly conserved protein initially identified as calregulin, a prominent Ca-binding protein of the endoplasmic reticulum (ER). Subsequent studies have established that CRT functions in the ER's protein folding response and Ca homeostatic mechanisms. An ER retention signal on the carboxyl terminus of CRT suggested that CRT was restricted to the ER.

View Article and Find Full Text PDF

The first-in-human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum-resistant ovarian and non-small cell lung cancer. A pharmacometric assessment evaluated farletuzumab ecteribulin pharmacokinetics and exposure-response (E-R) relationships for efficacy and safety to support dose optimization. Patients received 0.

View Article and Find Full Text PDF

Background: The preferred treatment option for patients with limited peritoneal metastasis (PM) is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC).While the textbook outcome (TO) concept has been applied to other complex surgeries, its prevalence, determinants, and impact in patients with PM remain unclear. This study sought to identify factors influencing TO among individuals with PM undergoing CRS+HIPEC in an Eastern European population.

View Article and Find Full Text PDF

Bernard-Soulier syndrome (BSS) is a rare qualitative condition of platelets wherein deficiency of platelet surface glycoproteins (GP) Ib, IX, and V forms the Ib-IX-V complex, leading to impaired hemostasis. Although it commonly presents as prolonged bleeding in general, women in the reproductive phase report additional complications during menstruation, pregnancy, and childbirth. In women of reproductive age, menorrhagia is a frequent complaint.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!